Metabolic syndrome and risk of development of chronic kidney disease: the Niigata preventive medicine study

Watanabe, Hiroshi; Obata, Hiroaki; Watanabe, Tôru; Sasaki, Shigeru; Nagai, Kojiro; Aizawa, Yoshifusa

doi:10.1002/dmrr.1058

Cited by 149 publications

(211 citation statements)

References 39 publications

Supporting

Mentioning

195

Contrasting

Unclassified

Order By: Relevance

“…A few longitudinal investigations have reported the association between prediabetes or non-diabetic hyperglycemia and the risk of albuminuria; the results are conflicting. 9,10,35 Most of these studies did not adjust for other cardiovascular risk factors, but in two population-based studies in persons without diabetes, increased FG in men and HbAR 1c R in both genders were found to be independent predictors of increased urinary albumin excretion. 22,36 However, neither of these studies excluded persons with diabetes at follow-up.…”

Section: Discussionmentioning

confidence: 99%

Prediabetes and Risk of Glomerular Hyperfiltration and Albuminuria in the General Nondiabetic Population: A Prospective Cohort Study

Melsom

Schei

Stefansson

et al. 2016

American Journal of Kidney Diseases

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prediabetes and Risk of Glomerular Hyperfiltration and Albuminuria in the General Nondiabetic Population: A Prospective Cohort Study

Melsom

Schei

Stefansson

et al. 2016

American Journal of Kidney Diseases

View full text Add to dashboard Cite

“…The sample size of included studies ranged from 176 to 17039 patients with MetS. Three studies included United States or European populations (10 -12), whereas eight studies included Asian populations (13,14,(21)(22)(23)(24)(25)(26). Follow-up duration ranged from 3.5 to 12 years.…”

Section: Statistical Analysesmentioning

confidence: 99%

“…Nine studies excluded participants with diabetes (10 -12,14,22-26). Five studies used the modified NCEP-ATP III criteria for diagnosis of MetS (14,21,22,25,26); three studies used the NCEP-ATP III criteria (10,12,23); two studies examined both the modified NCEP-ATP III and IDF definitions (11,24); and one study classified patients as having MetS on the basis of modified NCEP-ATP III, NCEP-ATP III, and IDF definitions (13). For studies in Asian populations that reported more than one definition, we selected outcomes using the modified NCEP-ATP III criteria for this analysis.…”

Section: Statistical Analysesmentioning

confidence: 99%

“…For studies in Asian populations that reported more than one definition, we selected outcomes using the modified NCEP-ATP III criteria for this analysis. Three studies used body mass index (BMI) Ն25 kg/m 2 instead of waist circumference to assess obesity (14,25,26) because of a lack of data. Only four studies reported the use of creatinine calibration (10,13,14,25).…”

Section: Statistical Analysesmentioning

confidence: 99%

“…Ten studies reported MetS and the outcome of development of eGFR Ͻ60 ml/min per 1.73 m 2 , of which three studies also reported the outcome of microalbuminuria or proteinuria separately (12,14,26). One study reported MetS and the outcome of proteinuria alone (11).…”

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Metabolic Syndrome and Kidney Disease

Thomas

Sehgal

Kashyap

et al. 2011

Clinical Journal of the American Society of Nephrology

465

322

View full text Add to dashboard Cite

SummaryBackground and objectives Observational studies have reported an association between metabolic syndrome (MetS) and microalbuminuria or proteinuria and chronic kidney disease (CKD) with varying risk estimates. We aimed to systematically review the association between MetS, its components, and development of microalbuminuria or proteinuria and CKD.Design, setting, participants and measurements and population We searched MEDLINE (1966 to October 2010), SCOPUS, and the Web of Science for prospective cohort confidence interval (CI) studies that reported the development of microalbuminuria or proteinuria and/or CKD in participants with MetS. Risk estimates for eGFR Ͻ60 ml/min per 1.73 m 2 were extracted from individual studies and pooled using a random effects model. The results for proteinuria outcomes were not pooled because of the small number of studies.Results Eleven studies (n ϭ 30,146) were included. MetS was significantly associated with the development of eGFR Ͻ60 ml/min per 1.73 m 2 (odds ratio, 1.55; 95% CI, 1.34, 1.80). The strength of this association seemed to increase as the number of components of MetS increased (trend P value ϭ 0.02). In patients with MetS, the odds ratios (95% CI) for development of eGFR Ͻ60 ml/min per 1.73 m 2 for individual components of MetS were: elevated blood pressure 1

show abstract

What Do We Currently Know About Metabolic Syndrome and Atrial Fibrillation?

Tadić

Ivanović

Cuspidi

2013

Clinical Cardiology

View full text Add to dashboard Cite

Metabolic syndrome represents a cluster of atherogenic risk factors including hypertension, insulin resistance, obesity, and dyslipidemia. Considering that all of these risk factors could influence the development of atrial fibrillation, an association between atrial fibrillation and the metabolic syndrome has been suggested. Additionally, oxidative stress and inflammation have been involved in the pathogenesis of both metabolic syndrome and atrial fibrillation. The mechanisms that relate metabolic syndrome to the increased risk of atrial fibrillation occurrence are not completely understood. Metabolic syndrome and atrial fibrillation are associated with increased cardiovascular morbidity and mortality. Because atrial fibrillation is the most common arrhythmia, and along with the prevalence of metabolic syndrome constantly increasing, it would be very important to determine the relationship between these 2 entities, especially due to the fact that the risk factors of metabolic syndrome are mainly correctable. This review focused on the available evidence supporting the association between metabolic syndrome components and metabolic syndrome as a clinical entity with atrial fibrillation. IntroductionMetabolic syndrome (MS) represents a cluster of cardiovascular (CV) and metabolic derangements (ie, increased blood pressure, abdominal obesity, insulin resistance, and dyslipidemia), which deteriorate vascular function and cause subclinical damage in a variety of organs, more than traditional risk factors individually.1 Atrial fibrillation (AF) is certainly the most prevalent arrhythmia in everyday clinical practice, and its prevalence increases parallel to MS frequency. 2 Each of the MS components are related to increased risk for AF occurrence. However, the exact mechanisms of these relationships have not been studied enough. Because both of these conditions are associated with significant CV and cerebrovascular morbidity and mortality, it is important to assess the relationship between these 2 frequent conditions and to determine the mechanisms that connect them.For the purpose of this review article, we used PubMed, Medline, OVID, and EMBASE databases and searched for the studies published

show abstract

Metabolic syndrome and risk of development of chronic kidney disease: the Niigata preventive medicine study

Abstract: The metabolic syndrome was associated with kidney disease even in subjects without major classical risk factors for chronic kidney disease.

Cited by 149 publications

References 39 publications

Prediabetes and Risk of Glomerular Hyperfiltration and Albuminuria in the General Nondiabetic Population: A Prospective Cohort Study

Prediabetes and Risk of Glomerular Hyperfiltration and Albuminuria in the General Nondiabetic Population: A Prospective Cohort Study

Metabolic Syndrome and Kidney Disease

What Do We Currently Know About Metabolic Syndrome and Atrial Fibrillation?

Contact Info

Product

Resources

About